Prado et al., (2024, November). “Meta-analysis of subjects with obesity from 4 RCTs supports potential of enobosarm to optimize weight loss”. Poster presented at the Obesity Week in San Antonio, Texas. November 2024|Enobosarm, Obesity|
Steiner et al., (2024, October). “Advancing enobosarm, an oral novel Selective Androgen Receptor Modulator (SARM), to avoid muscle loss and augment fat loss when combined with a Glucagon-Like Peptide-1 Receptor Agonist (GLP-1 RA) drugs for potentially higher quality weight loss”. Slides presented at the 4th Edition of World Obesity and Weight Management Congress in Baltimore, Maryland. October 2024|Enobosarm, Obesity|
Prado et al., (2024, June). “Potential to Optimize Weight Loss with Enobosarm: Meta-analysis of Body Composition from Three Randomized Clinical Trials Support the Ability of Enobosarm to Preserve Muscle while Reducing Fat”. Poster presented at the 2024 American Diabetes Association in Orlando, FL. June 2024|Enobosarm, Obesity|
Dobs et al., (2024, June). “Pooled Safety Analysis of Enobosarm from Phase 2 and Phase 3 Placebo-Controlled Clinical Trials”. Poster presented at the 2024 American Diabetes Association in Orlando, FL. June 2024|Enobosarm, Obesity|
Crawford et al., (2024, May). “Potential to Optimize Weight Loss with Enobosarm: Augment Reduction of Fat Mass while Preserving Muscle in Older Patients with Obesity”. Poster presented at the 2024 American Association of Clinical Endocrinology, New Orleans, LA. May 2024|Enobosarm, Obesity|
